Heterogeneity of response to lipid-lowering therapy

被引：2
|
作者：
Bach, RG [1 ]
机构：
[1] Washington Univ, Med Ctr, Cardiac Intens Care Unit, St Louis, MO 63110 USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2001年 / 38卷 / 07期
关键词：
D O I：
10.1016/S0735-1097(01)01622-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2136 / 2137
页数：2
相关论文
共 50 条
  • [31] Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy
    Biccire, Flavio G.
    Haner, Jonas
    Losdat, Sylvain
    Ueki, Yasushi
    Shibutani, Hiroki
    Otsuka, Tatsuhiko
    Kakizaki, Ryota
    Hofbauer, Thomas M.
    van Geuns, Robert-Jan
    Stortecky, Stefan
    Siontis, George C. M.
    Bar, Sarah
    Lonborg, Jacob
    Heg, Dik
    Kaiser, Christoph
    Spirk, David
    Daemen, Joost
    Iglesias, Juan F.
    Windecker, Stephan
    Engstrom, Thomas
    Lang, Irene
    Koskinas, Konstantinos C.
    Raber, Lorenz
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (18) : 1737 - 1747
  • [32] Genetic determinants of lipid-lowering response to atorvastatin therapy in an Indian population
    Kadam, P.
    Ashavaid, T. F.
    Ponde, C. K.
    Rajani, R. M.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (03) : 329 - 333
  • [33] Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
    Gaudet, Daniel
    Drouin-Chartier, Jean-Philippe
    Couture, Patrick
    CANADIAN JOURNAL OF CARDIOLOGY, 2017, 33 (07) : 872 - 882
  • [34] Lowering inflammation through lipid-lowering therapy: are we there yet?
    Agarwal, Nayan
    Golwala, Harsh
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2020, 6 (02) : 93 - 94
  • [35] Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome
    Nakao, Sho
    Ishihara, Takayuki
    Tsujimura, Takuya
    Iida, Osamu
    Hata, Yosuke
    Toyoshima, Taku
    Higashino, Naoko
    Mano, Toshiaki
    JOURNAL OF CARDIOLOGY, 2022, 79 (03) : 391 - 399
  • [36] Should smoking be an indication for lipid-lowering therapy?
    Peeters, A
    Demos, LL
    McNeil, JJ
    MEDICAL JOURNAL OF AUSTRALIA, 1999, 170 (05) : 240 - 240
  • [37] Adherence with concomitant antihypertensive and lipid-lowering therapy
    Chapman, RH
    Benner, JS
    Petrilla, AA
    Tierce, JC
    Battleman, DS
    Schwartz, S
    CIRCULATION, 2003, 108 (17) : 756 - 757
  • [38] Perspectives on lipid-lowering therapy: Past and present
    Gotto, AM
    MULTIPLE RISK FACTORS IN CARDIOVASCULAR DISEASE: STRATEGIES OF PREVENTION OF CORONARY HEART DISEASE, CARDIAC FAILURE, AND STROKE, 1998, 12 : 25 - 33
  • [39] FREQUENCY AND LIPID-LOWERING THERAPY OF EXTREME HYPERTRIGLYCERIDEMIA
    Gurtsiev, Timur
    Chubykina, Uliana
    Tyurina, Alexandra
    Sokolov, Alexei
    Ezhov, Marat
    ATHEROSCLEROSIS, 2024, 399
  • [40] Lipid-lowering therapy in chronic kidney disease
    Fernández-Vega, F
    NEFROLOGIA, 2004, 24 (06): : 113 - 126
12345